{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:04:57Z","timestamp":1785470697876,"version":"3.56.0"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.573677","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T04:36:32Z","timestamp":1600144592000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Centrally Acting Angiotensin-Converting Enzyme Inhibitor Suppresses Type I Interferon Responses and Decreases Inflammation in the Periphery and the CNS in Lupus-Prone Mice"],"prefix":"10.3389","volume":"11","author":[{"given":"Cassandra","family":"Nocito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Lubinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Hand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabeeya","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulsi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alecia","family":"Seliga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malika","family":"Winfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Zuluaga-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangdang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"Unterwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Persidsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Sriram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/sji.12330","article-title":"Systemic lupus erythematosus\u2013a disease with a dysregulated type I interferon system.","volume":"82","author":"Hagberg","year":"2015","journal-title":"Scand J Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1177\/0961203310371161","article-title":"The interferon-alpha signature of systemic lupus erythematosus.","volume":"19","author":"Obermoser","year":"2010","journal-title":"Lupus."},{"key":"B3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0165-0327(02)00264-1","article-title":"Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus.","volume":"72","author":"Bonaccorso","year":"2002","journal-title":"J Affect Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1212\/WNL.45.5.947","article-title":"Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia.","volume":"45","author":"Pavol","year":"1995","journal-title":"Neurology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11926-001-0020-7","article-title":"Neuropsychiatric lupus.","volume":"3","author":"Hanly","year":"2001","journal-title":"Curr Rheumatol Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/0961203313477227","article-title":"Depression and systemic lupus erythematosus: a systematic review.","volume":"22","author":"Palagini","year":"2013","journal-title":"Lupus."},{"key":"B7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40265-015-0534-3","article-title":"Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives.","volume":"76","author":"Magro-Checa","year":"2016","journal-title":"Drugs."},{"key":"B8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.rdc.2009.12.008","article-title":"Interferon-alpha: a therapeutic target in systemic lupus erythematosus.","volume":"36","author":"Crow","year":"2010","journal-title":"Rheum Dis Clin North Am."},{"key":"B9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.trsl.2014.10.005","article-title":"Targeting of type I interferon in systemic autoimmune diseases.","volume":"165","author":"Crow","year":"2015","journal-title":"Transl Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.clim.2013.02.013","article-title":"Anti-interferon alpha treatment in SLE.","volume":"148","author":"Kirou","year":"2013","journal-title":"Clin Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an Anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00156","article-title":"Kallikrein\u2013kinin system suppresses type i interferon responses: a novel pathway of interferon regulation.","volume":"9","author":"Seliga","year":"2018","journal-title":"Front Immunol."},{"key":"B14","first-page":"1","article-title":"Bioregulation of kinins: kallikreins, kininogens, and kininases.","volume":"44","author":"Bhoola","year":"1992","journal-title":"Pharmacol Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1113\/expphysiol.2004.028464","article-title":"Kallikrein-kinin in stroke, cardiovascular and renal disease.","volume":"90","author":"Chao","year":"2005","journal-title":"Exp Physiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1254\/jphs.SRJ05001X","article-title":"The kallikrein-kinin system: current and future pharmacological targets.","volume":"99","author":"Moreau","year":"2005","journal-title":"J Pharmacol Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pneurobio.2018.01.003","article-title":"Implication of the kallikrein-kinin system in neurological disorders: quest for potential biomarkers and mechanisms.","volume":"16","author":"Nokkari","year":"2018","journal-title":"Prog Neurobiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40256-016-0173-4","article-title":"Unraveling the pivotal role of bradykinin in ace inhibitor activity.","volume":"16","author":"Taddei","year":"2016","journal-title":"Am J Cardiovasc Drugs."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20180776","article-title":"Lupus antibodies induce behavioral changes mediated by microglia and blocked by ACE inhibitors.","volume":"215","author":"Nestor","year":"2018","journal-title":"J Exp Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"19854","DOI":"10.1073\/pnas.0608397104","article-title":"Human lupus autoantibodies against NMDA receptors mediate cognitive impairment.","volume":"103","author":"Kowal","year":"2006","journal-title":"Proc Natl Acad Sci USA."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/art.23399","article-title":"Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus.","volume":"58","author":"Arinuma","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1212\/01.WNL.0000140705.23869.E9","article-title":"Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression.","volume":"63","author":"Ohrui","year":"2004","journal-title":"Neurology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2174\/13894501113149990154","article-title":"Inflammation, serotonin and major depression.","volume":"14","author":"Catena-Dell\u2019Osso","year":"2013","journal-title":"Curr Drug Targets."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125109","article-title":"Type I interferon-mediated skewing of the serotonin synthesis is associated with severe disease in systemic lupus erythematosus.","volume":"10","author":"Lood","year":"2015","journal-title":"PLoS One."},{"key":"B25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/npp.1994.23","article-title":"Platelet serotonin and plasma tryptophan in depressed patients: effect of drug treatment and clinical outcome.","volume":"10","author":"Karege","year":"1994","journal-title":"Neuropsychopharmacology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.4049\/jimmunol.174.5.2499","article-title":"IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB\/c mice.","volume":"174","author":"Mathian","year":"2005","journal-title":"J Immunol."},{"key":"B27","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.4049\/jimmunol.158.12.6019","article-title":"Functional dissection of systemic lupus erythematosus using congenic mouse strains.","volume":"158","author":"Morel","year":"1997","journal-title":"J Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.clim.2010.03.008","article-title":"Effect of combining ACE inhibitor and statin in lupus-prone mice.","volume":"136","author":"Shimazu","year":"2010","journal-title":"Clin Immunol."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1065-0","article-title":"Secoisolariciresinol diglucoside is a blood-brain barrier protective and anti-inflammatory agent: implications for neuroinflammation.","volume":"15","author":"Rom","year":"2018","journal-title":"J Neuroinflammation."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1097\/QAD.0b013e3283081e08","article-title":"Peroxisome proliferator-activated receptor-gamma activation suppresses HIV-1 replication in an animal model of encephalitis.","volume":"22","author":"Potula","year":"2008","journal-title":"AIDS."},{"key":"B31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.clim.2016.08.019","article-title":"CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus.","volume":"185","author":"Chalmers","year":"2017","journal-title":"Clin Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cyto.2008.12.001","article-title":"TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells.","volume":"46","author":"Gao","year":"2009","journal-title":"Cytokine."},{"key":"B33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jneuroim.2008.11.009","article-title":"Depression is an early disease manifestation in lupus-prone MRL\/lpr mice.","volume":"207","author":"Gao","year":"2009","journal-title":"J Neuroimmunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.physbeh.2013.05.012","article-title":"Factors influencing behavior in the forced swim test.","volume":"118","author":"Bogdanova","year":"2013","journal-title":"Physiol Behav."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/207504","article-title":"The MRL\/lpr mouse strain as a model for neuropsychiatric systemic lupus erythematosus.","volume":"2011","author":"Gulinello","year":"2011","journal-title":"J Biomed Biotechnol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1078\/0940-2993-00301","article-title":"Behavioral phenotyping of mice in pharmacological and toxicological research.","volume":"55","author":"Karl","year":"2003","journal-title":"Exp Toxicol Pathol."},{"key":"B37","article-title":"The behavioral assessment of sensorimotor processes in the mouse: acoustic startle, sensory gating, locomotor activity, rotarod, and beam walking.","author":"Curzon","year":"2009","journal-title":"Methods of Behavior Analysis in Neuroscience. Frontiers in Neuroscience."},{"key":"B38","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1759-1961.2012.00032.x","article-title":"Effects of prolonged treatment with memantine in the MRL model of CNS lupus.","volume":"3","author":"Marcinko","year":"2012","journal-title":"Clin Exp Neuroimmunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0091-3057(95)00138-M","article-title":"Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety.","volume":"52","author":"Rodgers","year":"1995","journal-title":"Pharmacol Biochem Behav."},{"key":"B40","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S0149-7634(96)00058-9","article-title":"Anxiety, defence and the elevated plus-maze.","volume":"21","author":"Rodgers","year":"1997","journal-title":"Neurosci Biobehav Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00213-010-1980-y","article-title":"A role for delta opioid receptors in the central nucleus of the amygdala in anxiety-like behaviors.","volume":"212","author":"Randall-Thompson","year":"2010","journal-title":"Psychopharmacology (Berl)."},{"key":"B42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0165-0270(85)90031-7","article-title":"Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat.","volume":"14","author":"Pellow","year":"1985","journal-title":"J Neurosci Methods."},{"key":"B43","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4049\/jimmunol.1101686","article-title":"Myeloid dendritic cells from B6.NZM Sle1\/Sle2\/Sle3 lupus-prone mice express an IFN signature that precedes disease onset.","volume":"189","author":"Sriram","year":"2012","journal-title":"J Immunol."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64349-x","article-title":"Hyperglycemia and advanced glycation end products disrupt BBB and promote occludin and claudin-5 protein secretion on extracellular microvesicles.","volume":"10","author":"Rom","year":"2020","journal-title":"Sci Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"7297","DOI":"10.4049\/jimmunol.0803565","article-title":"Poly(ADP-ribose) polymerase-1 regulates the progression of autoimmune nephritis in males by inducing necrotic cell death and modulating inflammation.","volume":"182","author":"Jog","year":"2009","journal-title":"J Immunol."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/271694","article-title":"Murine models of systemic lupus erythematosus.","volume":"2011","author":"Perry","year":"2011","journal-title":"J Biomed Biotechnol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/nature03464","article-title":"IRF-7 is the master regulator of type-I interferon-dependent immune responses.","volume":"434","author":"Honda","year":"2005","journal-title":"Nature."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1002\/art.24803","article-title":"Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study.","volume":"60","author":"Bauer","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B49","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/ar290","article-title":"The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1\/Th2 paradigm in autoimmunity.","volume":"3","author":"Theofilopoulos","year":"2001","journal-title":"Arthritis Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S0377-1237(09)80120-2","article-title":"Serum serotonin abnormality in depression.","volume":"65","author":"Saldanha","year":"2009","journal-title":"Med J Armed Forces India."},{"key":"B51","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants.","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch Int Pharmacodyn Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev.immunol.23.021704.115843","article-title":"Type I interferons (alpha\/beta) in immunity and autoimmunity.","volume":"23","author":"Theofilopoulos","year":"2005","journal-title":"Annu Rev Immunol."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/0471142301.ns0810as55","article-title":"Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice.","author":"Castagne","year":"2011","journal-title":"Curr Protoc Neurosci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/hmg\/ddg128","article-title":"Genetic dissection of anxiety in autoimmune disease.","volume":"12","author":"Nakamura","year":"2003","journal-title":"Hum Mol Genet."},{"key":"B55","first-page":"17","article-title":"Predictors of renal involvement in patients with systemic lupus erythematosus.","volume":"25","author":"Satirapoj","year":"2007","journal-title":"Asian Pac J Allergy Immunol."},{"key":"B56","first-page":"251","article-title":"Rheumatoid arthritis and systemic lupus erythematosus as immune complex diseases.","volume":"67","author":"Weissmann","year":"2009","journal-title":"Bull NYU Hosp Jt Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood.","volume":"197","author":"Bennett","year":"2003","journal-title":"J Exp Med."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124203","article-title":"Tertiary lymphoid structures in the choroid plexus in neuropsychiatric lupus.","volume":"4","author":"Stock","year":"2019","journal-title":"JCI Insight."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00230","article-title":"A novel microglia-specific transcriptional signature correlates with behavioral deficits in neuropsychiatric lupus.","volume":"11","author":"Makinde","year":"2020","journal-title":"Front Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/nri1900","article-title":"IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors.","volume":"6","author":"Honda","year":"2006","journal-title":"Nat Rev Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jdermsci.2004.03.001","article-title":"Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis.","volume":"35","author":"Fujii","year":"2004","journal-title":"J Dermatol Sci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1007\/s00296-012-2393-5","article-title":"Serum levels of selected chemokines in systemic lupus erythematosus patients.","volume":"33","author":"Hrycek","year":"2013","journal-title":"Rheumatol Int."},{"key":"B63","doi-asserted-by":"publisher","first-page":"292","DOI":"10.4081\/reumatismo.2013.719","article-title":"Urinary CXCL10: a marker of nephritis in lupus patients.","volume":"65","author":"Marie","year":"2013","journal-title":"Reumatismo."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1006\/cyto.2000.0757","article-title":"Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus.","volume":"12","author":"Narumi","year":"2000","journal-title":"Cytokine."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-12-16","article-title":"Blood gene expression profiling in pediatric systemic lupus erythematosus and systemic juvenile idiopathic arthritis: from bench to bedside.","volume":"12","author":"Gilbert","year":"2014","journal-title":"Pediatr Rheumatol Online J."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2548142","article-title":"Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus.","volume":"2018","author":"Khajezadeh","year":"2018","journal-title":"Neurol Res Int."},{"key":"B67","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1177\/0961203319853621","article-title":"Depressive and anxiety symptom prevalence in childhood-onset systemic lupus erythematosus: a systematic review.","volume":"28","author":"Quilter","year":"2019","journal-title":"Lupus."},{"key":"B68","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/art.1780350410","article-title":"Interferon-alpha in lupus psychosis.","volume":"35","author":"Shiozawa","year":"1992","journal-title":"Arthritis Rheum."},{"key":"B69","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.bbr.2015.07.015","article-title":"Interferon-alpha treatment induces depression-like behaviour accompanied by elevated hippocampal quinolinic acid levels in rats.","volume":"293","author":"Fischer","year":"2015","journal-title":"Behav Brain Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"E351","DOI":"10.25011\/cim.v31i6.4921","article-title":"Reduction of cerebrospinal fluid and plasma serotonin in patients with post-stroke depression: a preliminary report.","volume":"31","author":"Gao","year":"2008","journal-title":"Clin Invest Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.biopsych.2004.02.009","article-title":"Cytokines and psychopathology: lessons from interferon-alpha.","volume":"56","author":"Capuron","year":"2004","journal-title":"Biol Psychiatry."},{"key":"B72","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE).","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B73","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1002\/eji.200737815","article-title":"Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms.","volume":"37","author":"Barrat","year":"2007","journal-title":"Eur J Immunol."},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1186\/ar1888","article-title":"Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus.","volume":"8","author":"Lenert","year":"2006","journal-title":"Arthritis Res Ther."},{"key":"B75","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses.","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.4049\/jimmunol.1201477","article-title":"Anti-IFN-alpha\/beta receptor antibody treatment ameliorates disease in lupus-predisposed mice.","volume":"189","author":"Baccala","year":"2012","journal-title":"J Immunol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.4049\/jimmunol.173.3.2134","article-title":"Type I IFN protects against murine lupus.","volume":"173","author":"Hron","year":"2004","journal-title":"J Immunol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1177\/0961203319872265","article-title":"Anti-IFNAR treatment does not reverse neuropsychiatric disease in MRL\/lpr lupus mice.","volume":"28","author":"Huang","year":"2019","journal-title":"Lupus."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/rheumatology\/ken208","article-title":"Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus\u2013results from LUMINA (LIX): a multiethnic US cohort.","volume":"47","author":"Duran-Barragan","year":"2008","journal-title":"Rheumatology (Oxford)."},{"key":"B80","doi-asserted-by":"publisher","first-page":"S684","DOI":"10.1097\/00004872-198812040-00215","article-title":"Effect of captopril on murine systemic lupus erythematosus disease.","volume":"6","author":"Herlitz","year":"1988","journal-title":"J Hypertens Suppl."},{"key":"B81","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/j.1523-1755.2004.00462.x","article-title":"An ACE inhibitor reduces Th2 cytokines and TGF-beta1 and TGF-beta2 isoforms in murine lupus nephritis.","volume":"65","author":"De Albuquerque","year":"2004","journal-title":"Kidney Int."},{"key":"B82","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/BF02003227","article-title":"Differential effects of captopril and enalapril, two angiotensin converting enzyme inhibitors, on immune reactivity in experimental lupus disease.","volume":"31","author":"Tarkowski","year":"1990","journal-title":"Agents Actions."},{"key":"B83","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1124\/jpet.103.053678","article-title":"Angiotensin inhibition reduces glomerular damage and renal chemokine expression in MRL\/lpr mice.","volume":"307","author":"Perez De Lema","year":"2003","journal-title":"J Pharmacol Exp Ther."},{"key":"B84","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cellimm.2009.09.006","article-title":"The ACE inhibitors enalapril and captopril modulate cytokine responses in Balb\/c and C57Bl\/6 normal mice and increase CD4(+)CD103(+)CD25(negative) splenic T cell numbers.","volume":"260","author":"Albuquerque","year":"2010","journal-title":"Cell Immunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/s11481-016-9703-8","article-title":"Angiotensin converting enzyme inhibitors ameliorate brain inflammation associated with microglial activation: possible implications for Alzheimer\u2019s disease.","volume":"11","author":"Torika","year":"2016","journal-title":"J Neuroimmune Pharmacol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/00005344-198409000-00016","article-title":"Suppressive effect of captopril on platelet aggregation in essential hypertension.","volume":"6","author":"Someya","year":"1984","journal-title":"J Cardiovasc Pharmacol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s00392-006-0363-1","article-title":"Differential antiplatelet effects of angiotensin converting enzyme inhibitors: comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril.","volume":"95","author":"Skowasch","year":"2006","journal-title":"Clin Res Cardiol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1515\/JBCPP.2003.14.4.323","article-title":"Captopril and enalapril improve cognition and depressed mood in hypertensive patients.","volume":"14","author":"Braszko","year":"2003","journal-title":"J Basic Clin Physiol Pharmacol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/00132580-200211000-00007","article-title":"Are antihypertensive agents protective against dementia? A review of clinical and preclinical data.","volume":"4","author":"Frishman","year":"2002","journal-title":"Heart Dis."},{"key":"B90","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/1440-1681.12210","article-title":"Enalapril attenuates ischaemic brain oedema and protects the blood-brain barrier in rats via an anti-oxidant action.","volume":"41","author":"Panahpour","year":"2014","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1071-9164(97)90047-6","article-title":"Antihypertensive and cardioprotective effects after angiotensin-converting enzyme inhibition: role of kinins.","volume":"3","author":"Tschope","year":"1997","journal-title":"J Card Fail."},{"key":"B93","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1192\/bjpo.bp.116.004184","article-title":"Associations of centrally acting ACE inhibitors with cognitive decline and survival in Alzheimer\u2019s disease.","volume":"3","author":"Fazal","year":"2017","journal-title":"BJPsych Open."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/art.40933","article-title":"Cognitive dysfunction in systemic lupus erythematosus: a case for initiating trials.","volume":"71","author":"Kello","year":"2019","journal-title":"Arthritis Rheumatol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.573677\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T09:23:26Z","timestamp":1696670606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.573677\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,15]]},"references-count":94,"alternative-id":["10.3389\/fimmu.2020.573677"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.573677","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,15]]},"article-number":"573677"}}